for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

7,909.00GBp

Change

202.00(+2.62%)

Volume

586,614

Today's Range

7,692.00

 - 

7,914.00

52 Week Range

5,312.00

 - 

8,227.89

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7,707.00
Open
7,739.00
Volume
586,614
3M AVG Volume
30.80
Today's High
7,914.00
Today's Low
7,692.00
52 Week High
8,227.89
52 Week Low
5,312.00
Shares Out (MIL)
1,312.14
Market Cap (MIL)
102,669.20
Forward P/E
28.31
Dividend (Yield %)
--

Next Event

Full Year 2019 AstraZeneca PLC Earnings Release

Latest Developments

More

FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Lynparza

AstraZeneca's Lynparza Gets FDA Priority Review For PAOLA-1 Trial

AstraZeneca Says To Discontinue Epanova Phase III Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.18 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

23.0K

2017

22.5K

2018

22.1K

2019(E)

24.3K
EPS (USD)

2016

4.310

2017

4.280

2018

3.460

2019(E)

3.587
Price To Earnings (TTM)
63.32
Price To Sales (TTM)
5.54
Price To Book (MRQ)
11.00
Price To Cash Flow (TTM)
23.32
Total Debt To Equity (MRQ)
149.28
LT Debt To Equity (MRQ)
144.53
Return on Investment (TTM)
4.49
Return on Equity (TTM)
3.26

Latest News

Latest News

AstraZeneca to discontinue Epanova trial, expects $100 million writedown

AstraZeneca <AZN.L> said on Monday it will discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects a $100 million (76.92 million pounds) writedown to hit its core profit in the fourth quarter.

AstraZeneca to discontinue Epanova trial, expects $100 mln writedown

AstraZeneca said on Monday it will discontinue a late-stage trial for Epanova to treat patients with mixed dyslipidaemia at high risk of cardiovascular disease and expects a $100 million writedown to hit its core profit in the fourth quarter.

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca <AZN.L> and Merck's <MRK.N> ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.

AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer

Dec 30 - AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.

AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA

(This Dec.20 story corrects first paragraph to say the approval came four months ahead of schedule, not three months, after FDA clarification)

AstraZeneca-Daiichi drug halts cancer for months in first readout

An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer.

RPT-AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

AstraZeneca shares rise on early U.S. approval for leukaemia drug

AstraZeneca <AZN.L> shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie <ABBV.N>.

AstraZeneca succeeds in treating lupus in late-stage study

AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study.

Britain's AstraZeneca launches $1 billion China investment fund with CICC

AstraZeneca <AZN.L> said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

AstraZeneca to distribute Sun Pharma cancer drugs in China

Top Indian drugmaker Sun Pharmaceutical Industries Ltd <SUN.NS> said on Wednesday Britain's AstraZeneca <AZN.L> would distribute some of Sun's cancer treatment drugs in China, the world's second-largest pharmaceutical market.

Britain's AstraZeneca to distribute Sun Pharma cancer drugs in China

Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday it would introduce some of its cancer treatment drugs in China through Britain's AstraZeneca.

AstraZeneca sells European rights for schizophrenia drug to Cheplapharm

AstraZeneca Plc <AZN.L> said on Wednesday it plans to sell the European and Russian rights for a schizophrenia drug to German firm Cheplapharm Arzneimittel for an upfront payment of $178 million, as the British drugmaker looks to offload older drugs.

AstraZeneca's combo drug for lung cancer succeeds in late-stage trial

AstraZeneca Plc said on Monday a combination of its cancer drug, Imfinzi, along with chemotherapy helped curb progression of lung cancer in a late-stage study, sending its shares up as much as 2%.

AstraZeneca cancer drug combo meets late-stage trial goal

AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.

AstraZeneca raises sales forecast after surge in cancer drugs

AstraZeneca <AZN.L> lifted its annual drug sales forecast for the second time this year after a surge in revenue from newer cancer treatments, but warned that changing policies in China, its second-biggest market, would crimp growth next year.

FTSE 100 heads for fourth session of gains

London's FTSE 100 held firm at a near one-month high on Thursday as gains in AstraZeneca after a 2019 target upgrade countered losses in Royal Bank of Scotland following a weak third-quarter update, while midcaps outperformed as sterling rose.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up